Novo Nordisk’s obesity drug Wegovy has been cleared by US regulators to treat a type of liver disease that often affects people with obesity. The FDA granted accelerated approval for patients with metabolic dysfunction-associated steatohepatitis (MASH), which is characterized by moderate to advanced liver scarring. Clinical trials showed the drug improves liver scarring and resolves symptoms, offering new hope for those at risk of more severe complications such as cirrhosis, liver cancer, or a liver transplant.
Source: https://www.statnews.com/2025/08/15/wegovy-mash-novo-nordisk